Villanova Investment Management Co LLC Makes New Investment in Lantheus Holdings, Inc. $LNTH

Villanova Investment Management Co LLC bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 22,710 shares of the medical equipment provider’s stock, valued at approximately $1,511,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Smartleaf Asset Management LLC grew its stake in Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of Lantheus by 122.6% in the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 298 shares during the period. Osterweis Capital Management Inc. bought a new position in shares of Lantheus during the 2nd quarter worth $36,000. Los Angeles Capital Management LLC bought a new position in shares of Lantheus during the 4th quarter worth $39,000. Finally, Farther Finance Advisors LLC grew its position in shares of Lantheus by 71.4% during the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 275 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 0.7%

Shares of NASDAQ LNTH opened at $103.92 on Friday. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $107.99. The business has a fifty day moving average price of $92.89 and a 200 day moving average price of $78.06. The stock has a market capitalization of $6.77 billion, a P/E ratio of 25.04 and a beta of -0.03. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.21. The company had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities research analysts expect that Lantheus Holdings, Inc. will post 4.39 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on LNTH. B. Riley Financial restated a “buy” rating on shares of Lantheus in a report on Friday, May 1st. Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. William Blair reissued an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Citizens Jmp boosted their price target on shares of Lantheus from $85.00 to $115.00 and gave the company a “market outperform” rating in a report on Friday, May 8th. Finally, JonesTrading cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and an average target price of $101.86.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.